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Background: To explore the impact of geographical remoteness and area-level socioeconomic disadvantage on
colorectal cancer (CRC) survival.
Methods: Multilevel logistic regression and Markov chain Monte Carlo simulations were used to analyze
geographical variations in five-year all-cause and CRC-specific survival across 478 regions in Queensland Australia for
22,727 CRC cases aged 20–84 years diagnosed from 1997–2007.
Results: Area-level disadvantage and geographic remoteness were independently associated with CRC survival.
After full multivariate adjustment (both levels), patients from remote (odds Ratio [OR]: 1.24, 95%CrI: 1.07-1.42)
and more disadvantaged quintiles (OR = 1.12, 1.15, 1.20, 1.23 for Quintiles 4, 3, 2 and 1 respectively) had lower
CRC-specific survival than major cities and least disadvantaged areas. Similar associations were found for all-cause
survival. Area disadvantage accounted for a substantial amount of the all-cause variation between areas.
Conclusions: We have demonstrated that the area-level inequalities in survival of colorectal cancer patients cannot
be explained by the measured individual-level characteristics of the patients or their cancer and remain after
adjusting for cancer stage. Further research is urgently needed to clarify the factors that underlie the survival
differences, including the importance of geographical differences in clinical management of CRC.
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Worldwide, colorectal cancer (CRC) was the second
most common invasive cancer in 2008 and the fourth
most deadly form of cancer [1]. Advances in cancer pre-
vention, screening, and management over recent decades
[2] have contributed to the ongoing improvements in
CRC survival in developed countries [1] with Australia
having one of the highest survival rates globally [3].
However not all patients have benefited equally from
these advances, with international studies consistently
reporting survival inequalities by area disadvantage and
heath care access, [4-6] with evidence that these inequal-
ities may be widening [7]. Australians living outside
major cities, in socioeconomically disadvantaged regions* Correspondence: peterbaade@cancerqld.org.au
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reproduction in any medium, provided the oror further away from radiation facilities also have poorer
survival after a diagnosis of colon or rectal cancer
[8-11]. Inequities in oncology services and general health
care provision with increasing geographical isolation in
Australia have been well documented [12] and acknowl-
edged to be contributing factors to the greater burden
for remote cancer patients.
Nonetheless, relatively few studies have quantified the
impact that area-level factors have on geographical
inequalities in CRC survival while specifically consider-
ing the effect of the underlying nested geographical
structure [5,13]. Multilevel models enable us to simul-
taneously estimate the impact of both individual- and
area-level explanatory variables on the total variation in
individual outcomes while accounting for the clustering
of observations within the same geographical location.
Improved computing capacity has led to the increasing
adoption of sophisticated multilevel techniques for large-td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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equalities in cancer survival and explore underlying causes
[5,13-15].
A recent study examined the extent of spatial variation
in CRC relative survival across small areas in Queensland
[16]. However, that study was designed primarily to meas-
ure the impact that spatial variations had on premature
mortality and so utilized data aggregated over each region
and combinations of covariates. This removed any oppor-
tunity to simultaneously examine the impact that area-
and individual-level factors had on differences in survival
between individual patients.
In this study we explore whether geographical remote-
ness and socioeconomic characteristics of the area where
a CRC patient resides at diagnosis are associated with
their survival, independently of the characteristics of the
individual patients themselves. To the best of our know-
ledge it is the first Australian study to quantitatively assess
the independent associations between the characteristics
of geographical areas and the characteristics of individuals
in those areas with survival.
Specifically we aimed to:
i. assess whether all-cause and CRC-specific survival
varied with a patient’s area of residence while
controlling for within-area variation in individual
effects and between-group variation in area-level
factors;
ii. explore the independent impact of remoteness and
area disadvantage on survival after adjusting for
individual characteristics;
iii. identify individual-level factors influencing CRC
survival; and
iv. explore the effect of interactions between area-level
factors on survival.
Being able to quantify geographical variations in sur-
vival and identify associations with these disparities may
assist advocates and health planners to develop strategic
plans and public health interventions to reduce these
inequalities.
Methods
Ethical approval to conduct this study was obtained
from the University of Queensland Social and Behavioral
Sciences Ethical Review Committee. Queensland Health
provided legislative approval to access routinely collected
population-based cancer data in Queensland.
Study cohort
All incident cases of invasive CRC (ICD-O3 codes C18
to C20, C218) diagnosed between January 1, 1997 and
December 31, 2007 (inclusive) were extracted from the
state-wide population-based Queensland Cancer Registryto which all confirmed invasive cancers diagnosed among
Queensland residents must be legally reported. Data qual-
ity is high as evidenced by the low percentage (1.4%) of
death certificate notifications only and high percentage
(92.1%) of histologically verified cases in 2007 [17]. We
restricted our cohort to those aged between 20 and
84 years at diagnosis since CRC is relatively rare among
younger age groups, while among older patients death
certificates are less accurate [18] and their clinical man-
agement is different [19,20]. Cases were excluded if
they were notified by death certificate only, were first
identified at autopsy or could not be geocoded. For pa-
tients with multiple primary colon or rectal cancers,
only the tumor with the most advanced stage was con-
sidered. Variables extracted (categories in Table 1) in-
cluded year and age at diagnosis, gender, occupation,
marital status, country of birth, CRC site (colon C18;
rectum C19-C20,C218), differentiation and Indigenous
status, with the latter being considered sufficiently
complete for analysis [21].
Geocoding and travel distance calculations
Residential addresses were geocoded using full street
address (98.0% of cases), a street at the center of the
suburb (1.8%) or the post code (0.2%) at diagnosis.
Radiotherapy facilities in Queensland are concentrated
in larger cities and typically affiliated to major cancer
care centers; hence these distances are a proxy measure
of access to optimum cancer treatment. Geographical
Information System software and a street network data-
base were used to calculate road travel distances from
each patient’s geocoded location to the closest radiother-
apy facility as described previously [8]. These road travel
distances represent the minimum distance, since it is
possible that some patients may not have chosen the
closest facility for treatment.
Survival data
The study cohort was followed up to 31st December
2010. The Queensland Cancer Registry routinely all
incident cases to the Registrar of Births, Deaths and
Marriages and the National Death Index to ascertain
mortality status for all cancer patients diagnosed in
Queensland [17]. Additional data from hospitals and
pathology records are used to finalize the cause of
death thereby providing a high degree of accuracy;
although as with all population-based registries cause
of death misclassification remains a possibility. Sur-
vival was measured in years from date of diagnosis to
death or the study end point. Deaths from other
causes were censored when estimating CRC-specific
survival. The follow up time for patients who sur-
vived more than five years after diagnosis was cen-
sored at five years.
Table 1 Cohort description and unadjusted five year estimates of all-cause and colorectal cancer-specific outcomes for
colorectal cancer patients aged 20–84 in Queensland, 1997–2007
All-cause Colorectal cancer
sub group N (%) deaths (%) survival [95% CI] p deaths (%) survival [95% CI] p
All patients in cohort 22,727 41.1 58.1 [57, 58] 31.8 66.3 [66, 67]
Area-Remoteness Index of Australia (ARIA) < 0.001 < 0.001
Major city 13,155 (57.9) 39.6 59.6 [59, 60] 30.0 68.1 [68, 69]
Inner regional 5,139 (22.6) 41.4 57.8 [56, 59] 32.2 65.9 [65, 67]
Outer regional 3,485 (15.3) 45.1 54.1 [52,56] 36.0 61.6 [60, 63]
Remote1 948 (4.2) 46.2 53.1 [50,56] 38.2 59.6 [56, 63]
Index of Relative socioeconomic advantage and disadvantage (IRSAD) < 0.001 < 0.001
Quintile 5 (least disadvantaged) 3,193 (14.1) 36.4 62.8 [61, 65] 28.0 70.4 [69, 72]
Quintile 4 5,101 (22.4) 38.9 60.2 [59, 62] 29.8 68.3 [67, 70]
Quintile 3 6,075 (26.7) 41.0 58.2 [57, 59] 32.2 65.9 [65, 67]
Quintile 2 5,335 (23.5) 44.5 54.6 [53,56] 34.5 63.3 [62, 65]
Quintile 1 (most disadvantaged) 3,023 (13.3) 43.8 55.4 [54,57] 33.5 64.2 [62, 66]
Age group < 0.001 < 0.001
20 to 49 1,873 (8.2) 32.0 67.4 [65, 70] 29.3 69.8 [68, 72]
50 to 59 3,938 (17.3) 32.8 66.7 [65, 68] 29.7 69.3 [68, 71]
60 to 69 6,578 (28.9) 37.1 62.1 [61, 63] 30.7 67.8 [67, 69]
70 to79 7,718 (34.1) 45.6 53.5 [52,55] 32.4 64.8 [64, 66]
80 to 84 2,620 (11.5) 56.7 41.9 [40,44] 37.7 58.4 [56, 60]
Gender < 0.001 =0.003
Male 12,879 (56.7) 42.9 56.2 [55,57] 32.5 65.1 [64, 66]
Female 9,848 (43.3) 38.8 60.6 [60, 62] 30.8 67.7 [67, 69]
Indigenous status < 0.001 < 0.001
Non Indigenous 20,868 (91.8) 43.1 56.1 [55,57] 33.4 64.5 [64, 65]
Indigenous 181 (0.8) 45.3 53.7 [45, 61] 35.4 63.1 [55, 70]
Not stated 1,678 (7.4) 16.7 82.9 [81, 85] 11.3 88.3 [87, 90]
Marital status <0.001 < 0.001
Married 14,532 (63.9) 39.0 60.1 [59, 61] 30.8 67.4 [67, 68]
Never married/single 1,541 (6.8) 46.5 52.6 [50,55] 36.2 61.5 [59, 64]
Widowed 3,951 (17.4) 48.2 51.1 [49,52] 34.2 63.2 [62, 65]
Divorced 1,822 (8) 44.4 54.7 [52,57] 36.2 61.6 [59, 64]
Separated 454 (2) 31.9 67.3 [63, 71] 24.4 74.3 [70, 78]
Not stated 427 (1.9) 20.6 79.3 [75, 83] 15.5 84.2 [80, 87]
Occupation category < 0.001 < 0.001
Professional 4,783 (21.1) 48.6 50.6 [49,52] 39.0 58.4 [57, 60]
White collar 2,665 (11.7) 52.6 46.7 [44,49] 41.4 55.6 [54, 58]
Blue Collar 3,789 (16.7) 59.5 39.4 [38,41] 47.0 48.9 [47,51]
Not in labor force 7,529 (33.1) 33.5 65.9 [65, 67] 25.5 73.3 [72, 74]
Not stated/ Inadequately described 3,961 (17.4) 21.0 78.2 [77, 79] 14.0 85.2 [84, 86]
Country birth2 < 0.001 < 0.001
Australia 17,367 (76.4) 41.9 57.2 [57, 58] 32.3 65.7 [65, 66]
Other English-speaking 4,580 (20.2) 39.2 60.2 [59, 62] 30.7 67.8 [66, 69]
Non-English-speaking 780 (3.4) 34.0 64.2 [61, 68] 26.4 71.1 [67, 74]
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Table 1 Cohort description and unadjusted five year estimates of all-cause and colorectal cancer-specific outcomes for
colorectal cancer patients aged 20–84 in Queensland, 1997–2007 (Continued)
Site3 =0.003 < 0.001
Proximal(R) colon 7,874 (34.6) 41.8 57.5 [56, 59] 31.7 66.4 [64, 67]
Distal (L) colon 5,865 (25.9) 39.5 59.6 [58, 61] 30.0 68.8 [68,70]
Colon NOS 1,299 (5.7) 54.0 45.3 [43,48] 44.5 53.2 [50,56]
Rectal 7,689 (33.8) 39.4 59.8 [59, 60] 31.0 66.9 [65, 68]
Stage < 0.001 < 0.001
Stage A 4,332 (19.1) 18.3 81.1 [80, 83] 7.8 91.7 [91, 93]
Stage B 6,323 (27.8) 28.9 70.3 [69, 71] 18.1 80.4 [79, 81]
Stage C 5,846 (25.7) 47.9 50.8 [50,52] 39.6 57.5 [56, 58]
Stage D 2,576 (11.3) 84.7 13.9 [12,15] 80.6 15.6 [14,17]
Unknown stage 3,650 (16.1) 47.4 51.9 [50,54] 36.9 60.9 [59, 62]
Differentiation < 0.001 < 0.001
Well differentiated 1,107 (4.9) 31.9 67.3 [65, 70] 20.1 75.9 [76, 81]
Moderate differentiated 13,953 (61.4) 36.7 62.4 [62, 63] 27.4 70.7 [70, 71]
Poor differentiated 4,206 (18.5) 52.9 46.2 [45,48] 44.2 53.3 [52,55]
Not stated 3,461 (15.2) 47.2 52.2 [50,54] 38.0 60.3 [59, 62]
Surgical margins < 0.001 < 0.001
Clear 16,664 (73.4) 36.3 62.9 [62, 64] 26.9 71.2 [70, 72]
Positive 530 (2.3) 39.8 59.7 [55, 61] 31.1 67.3 [63, 71]
Unknown 5,533 (24.3) 55.7 43.6 [43,45] 46.4 51.2 [50,53]
Distance to Treatment < 0.001 < 0.001
0-99 km 16,042 (70.5) 39.4 59.7 [59, 61] 30.1 68.1 [67, 69]
100-399 km 5,173 (22.8) 44.9 54.4 [53,56] 35.2 62.3 [61, 64]
400 or more km 1,512 (6.7) 45.7 53.5 [51,54] 37.8 60.3 [58, 62]
CI = confidence interval; p-values calculated using log-rank test for equality of survivor functions restricting follow-up to five years for each patient.
1 Includes remote and very remote categories.
2 Other English-speaking: those born in New Zealand, United Kingdom, Ireland, or North America; non-English-speaking: those not born in Australia, New Zealand,
United Kingdom, Ireland or North America.
3 Colorectal sites defined as: proximal colon (ICDO3: C180 to C184), distal colon (ICDO3: C185-C187), unspecified colon (ICDO3: C188-C189) and rectal (ICDO3: C19-
C20, C218).
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Stage at diagnosis
As has been previously described, [8] information extracted
from pathology forms [22] was used to categorize stage at
diagnosis into four groups ranging from Stage I (least ad-
vanced) to IV (metastatic) based on the TNM system [23].
Surgical margins
The recorded information on the distance between the
tumor and outer edge of tissue sample removed during
biopsy or CRC resection was used to categorize patients
as having clear (no cancer cells at outer edge of sample),
positive (cancer cells present at or close to the edge) or
unknown surgical margins. Cancers that are recorded
with a clear margin are deemed to have been completely
excised which has been shown to be associated with
lower recurrence and better survival [24].Geographical area
Statistical Local Areas (SLA, n = 478) were used as the
geographical unit for this study as they are deemed to be
relatively homogenous with respect to population char-
acteristics and socioeconomic status. In 2006 there were
478 SLAs in Queensland with a median population of
5,810. Cancer incidence data across all years were
mapped to the 2006 SLA boundaries based on geocoded
location at diagnosis thereby removing any impact of
temporal changes in geographic boundaries.
Area-level socioeconomic disadvantage
Each patient was assigned to a quintile of area disad-
vantage (of increasing advantage from Quintile 1) based
on the Australian Bureau of Statistics-derived Index of
Relative Socioeconomic Advantage and Disadvantage
(IRSAD). The IRSAD is determined from census
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such as the proportion of tertiary educated residents and
the proportion of low income households in a SLA [25].
This index was chosen as it does not include Indigenous
status in its derivation.
Geographic remoteness
The address of usual residence at CRC diagnosis was
grouped according to their level of geographic remoteness
using the Australian Standard Geographical Classification
Remoteness Index [26], which is a purely geographic
measure of remoteness based on road distances from
population centers to various levels of service provision
(see Table 1 for categories).
Statistical analysis
The five-year all-cause and CRC-specific survival rates
were assessed using Kaplan-Meir analysis and estimates
compared across patient-sub groups with the log rank test.
Discrete-time multilevel logistic survival models
We carried out a full discrete-time multilevel logistic
survival analysis that retained the underlying nested
structure. This approach differs markedly from frailty
models [27] where random effects are used to model
clustering effects by adjusting the standard errors to
account for non-independence of data within clusters.
Frailty models offer a more restricted approach than
multilevel methods [28,29]. Multilevel models use mea-
sures of clustering and variance in informative ways and
can simultaneously model and partition the observed
variation across individual and area-levels [28,30,31].
They are increasingly the method of choice when analys-
ing data with a clear hierarchical structure [32].
Discrete-time multilevel logistic survival models are fit-
ted to an expanded person-period dataset, containing a se-
quence of binary responses for each individual from each
event time (in years). This variable is coded as 1 if an indi-
vidual dies during a time interval t (measured in years in
current analysis) and zero otherwise. Therefore a patient
who is censored is indicated by a sequence of zeros for
each t while one who dies will be denoted by value 1 for
year in which death occurred and zero for each previous
year. Once an individual dies data collection stops for that
person. Hence the discrete response for a person who died
during the third year following diagnosis would be (0, 0,
1), whereas it would be (0, 0, 0) if an individual was cen-
sored that year. Discrete-time multilevel survival models
are thus equivalent to fitting a logistic regression model to
the expanded dataset [14,33]. The restriction of follow-up
to 5 years enabled the efficient computation of these com-
plex models, which can be problematic when using this
approach for analyzing large population-based datasets
with long follow up intervals [33].Although continuous time models remain the most
popular for survival analysis, discrete-time methods have
several advantages, especially in the multilevel frame-
work when using large public health data sets [33,34].
Generating an expanded person-time dataset using
months or days, instead of years, would increase the size
of the dataset by more than ten or 300-fold [34]. Given
the size of our initial data set, this additional expansion
was not feasible. It is for this reason that discrete-time
methods, using years as the time variable, are preferred
in the multilevel framework.
The hazard function for a discrete-time multilevel logis-
tic survival model is the conditional probability of death in
interval t given that no death has occurred in the previous
intervals [33,34]. When the hazard is modelled using the
logit link, the exponentiated regression parameters are
interpreted as the odds ratios (OR) rather than hazard
ratios. Although the baseline hazard can be modelled
using dummy variables for each time interval, in practice
efficient estimates of model parameters can be obtained
using low order polynomials for the time [35].
When the hazard is small, which is often the case if
time intervals are narrow or probability of death occur-
ring in time interval t is low (i.e. death is a rare event),
the parameter estimates from the logit and Cox models
are likely to comparable. Hence discrete-time logistic
regression may be considered as an approximation to
the Cox model [33,34]. An additional table demonstrates
this. (see Additional file 1, Additional file 2).
Discrete-time multilevel logistic survival analysis was
used to quantify the effect of area disadvantage and geo-
graphic remoteness on all-cause and CRC-specific survival
after adjusting for individual-level factors. Models were
fitted using Markov chain Monte Carlo (MCMC) [36]
simulations in MLwiN version 2.26 [37] (University of
Bristol, United Kingdom) interfaced with Stata (StataCorp,
Texas) [38]. Convergence was assessed by trace and dens-
ity plots, the autocorrelation of model parameters from
posterior distributions and diagnostic tests [36] with none
indicating non-convergence. After a burn in period of
40,000 iterations, parameter estimates were obtained from
a further 80,000 iterations (with every 10th iteration kept).
The underlying hazard was described with a second-order
polynomial (i.e. time (years) and time-squared) [14].
A systematic three-step approach was used for each out-
come. First we estimated null models that comprised indi-
viduals nested in SLAs without covariates. A significant
area-level random term (based on the Wald χ2) [37] sug-
gested that the modeled survival rates vary across areas in
Queensland. We then added individual covariates before
including area-level remoteness and neighborhood disad-
vantage (separately or simultaneously) with the full model
being simultaneously adjusted for all explanatory variables
on both levels. Interactions were tested (Wald χ2) by
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scrutinized variables in the models.
Model comparison
Models were compared using the Bayesian deviance
information criterion (DIC) [39] with smaller values
(with a difference of at least 7 units) indicating an im-
provement in model fit [39].
All available covariates (Table 1) were initially used for
the multivariate discrete-time multilevel logistic survival
analysis. We initially ran a series of MLwiN models
based on the likelihood method [37] to determine those
variables that were not significant (p > 0.20) and so ex-
cluded from the final models. To explore the impact of
unknown stage at diagnosis on model fit and summary
measures, sensitivity analyses were carried out by repeating
the all-cause and CRC-specific survival analyses under
three different assumptions; (a) all unstaged cases being re-
classified as Stage I, b) reclassified as Stage IV or c) equally
distributed over all four stage categories.
Fixed parameter estimates are presented as odds ratios
(OR) with their 95% credible intervals (CrI). Joint chi-
square tests were used to assess the contribution of each
variable to model fit.
The median odds ratio
The median odds ratio (MOR) [40,41] is a measure of
the variation between the mortality rates of different
SLAs that is not explained by the modeled risk factors.
It is expressed in terms of the odds ratio scale. If the
MOR is equal to 1 there is no difference between areas.
Larger values indicate greater geographical variation in
survival. The MOR was calculated for the discrete-time
multilevel logistic survival models as:




where Ζ0.75 is the 75th percentile of the normal distribu-
tion and σ2 is the estimated area-level variance from the
MCMC simulations. A 95% CrI for the MOR was gener-
ated from the posterior distribution of the variance [30].
The interval odds ratio
In multilevel modeling, the interpretation of an area-
level risk factor such as remoteness or area disadvantage
should be interpreted as the effect of the risk factor
given a comparison between two SLAs of identical
values of the random effect whose mortality probabilities
differ only in terms of the risk factor under consider-
ation [41]. Therefore, to interpret the area-level risk fac-
tors more generally, the unexplained between-area
variability also needs to be taken into account. This is
achieved using the 80% interval Odds Ratio (IOR) [30],
which shows the impact of area-level risk factors onmortality when comparing SLAs with different area-level
characteristics. The IOR is calculated as:




where β is the regression coefficient for the area-level
variable, σ2 is the area-level variance and Z0.10 and Z0.90
are the 10th and 90th centiles respectively of the stand-
ard normal distribution. If the IOR does not include 1.0
it indicates that the effect of the area-level variable is
large relative to the clustering effect of the SLAs.
Results
Study population
Between 1997 and 2007 there were 25,788 invasive CRC
cases in Queensland. Of these 23,634 were aged 20–
84 years at diagnosis who initially comprised the study
cohort. The exclusion of cases that had incomplete ad-
dress at diagnosis information (n = 723), were identified
at autopsy (n = 33), had death certificate notification only
(n = 126) or who survived for less than one day (n = 25)
gave the final cohort of 22,727 cases.
Among the final cohort (Table 1), approximately 37%
of cancers were diagnosed at advanced stage of which
one third (31%) had metastatic (Stage IV) disease. There
were 9,337 (41.1%) deaths during the first five years after
diagnosis of which 7,221 were attributed to CRC.
Bivariate Kaplan-Meier survival analysis
The unadjusted 5-year all-cause and CRC-survival rates
were 58.1% (95% CI: 57-58%) and 66.3% (95% CI: 66-67%)
respectively (Figure 1). For both survival measures
there was a difference of about 6–8 percentage points
between people living in the most remote areas and
those from major cities, and also between residents
of the most and least disadvantaged areas. (Table 1;
Figure 2) All-cause and CRC-specific survival de-
creased with increasing age, longer travel distances,
poorer tumor differentiation or higher stage at di-
agnosis with poorer survival also seen for patients
who were Indigenous, blue collar workers, unmarried,
males or born in non-English-speaking countries.
Discrete-time multilevel logistic survival analysis
Development of final all-cause survival model
Based on the DIC measure, model fit was markedly
improved by adding the individual effects to the null
model for all-cause survival (Model 2). Adding in re-
moteness (Model 3) or area disadvantage (Model 4) further
reduced the DIC by at least 7 units. Comparing the DIC stat-
istic of these models with the fully adjusted main-effects
model (Model 5) suggested that Model 5 provided an
improved fit (Table 2). The additional introduction of the
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Figure 1 Kaplan-Meir survival curves for the cumulative probability of all-cause and colorectal cancer-specific survival five years from
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Figure 2 Kaplan-Meir five-year survival curves (from diagnosis) for colorectal cancer patients aged 20–84 in Queensland, 1997–2007
by geographic remoteness (early: n = 13,155; inner regional: n = 5,139; outer regional: n = 3,485; remote: n = 948) and area
socio-economic disadvantage which was categorized into 5 quintiles of increasing advantage from Quintile 1 (Quintile 1: n = 3,023; 2:
n = 5,335; 3: n = 6,075; 4: 5,101; 5: 3,193). a) all-cause survival by remoteness b) colorectal cancer-specific survival by remoteness c) all-cause
survival by area disadvantage d) colorectal cancer-specific survival by area disadvantage.
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cause survival. Parameter estimates presented here refer to
this model.
Development of final CRC-specific survival model
The DIC statistic indicated that adjusting for indi-
vidual effects (Model 8) significantly improved fit over
the null model (Model 7). The DIC was further re-
duced by at least 7 units on introduction of remo-
teness (Model 9) or area disadvantage (Model 10).
Based on DIC criteria model fit was further improved
for the fully adjusted main-effects Model 11 (Table 2)
while overall fit of the interaction model (Model 12)
was poorer than its main-effects counterpart. There-
fore we considered model 11 to be best fitting model
for these CRC-survival data and used it for the re-
mainder of this analysis.Table 2 Measures of model fit and estimates of geographical
survival in Queensland, 1997–2007
Model description1 DIC2 Area-variance
All-cause survival
1 Null (no explanatory variables) 57769.71 0.025 (0.014, 0.0
2 Individual-level covariates5 46072.45 0.011 (0.006, 0.0
3 Individual-level covariates and
area-remoteness
46058.44 0.007 (0.003, 0.0
4 Individual-level covariates and
area-disadvantage
46054.03 0.006 (0.001, 0.0
5 Individual- and both area-level
covariates
46046.57 0.005 (0.001, 0.0
6 All covariates with area-level
interactions
46051.12 0.005 (0.001, 0.0
Colorectal cancer-specific survival
7 Null (no explanatory variables) 48609.89 0.021 (0.011, 0.0
8 Individual -level covariates 37013.72 0.008 (0.003, 0.0
9 Individual-level covariates and
area-remoteness
36987.44 0.003 (0.001, 0.0
10 Individual-level covariates and
area-disadvantage
36995.14 0.004 (0.001, 0.0
11 Individual- and both area-level
covariates
36979.49 0.002 (0.001, 0.0
12 All covariates with area-level
interactions
36993.31 0.003 (0.001, 0.0
CrI: credible interval for posterior distributions from Markov Chain Monte Carlo mul
1 All except null models adjusted for time (years after diagnosis), patient age at dia
differentiation and surgical margins. Models 3 and 9 also adjusted for area remoten
also adjusted for area remoteness and area disadvantage; Models 6 and 12 include
11 respectively.
2 DIC Deviance Information criterion. Model with a smaller DIC (Difference ≥ 7 units
be weakly distinguished.
3 The residual area-level variance from the multilevel models.
4 The percentage reduction in variance reflects the change in area-level variance re
5 MOR (median odds ratio) translate the area-level variance to the odds ratio scale.
individual in the area at highest risk and an individual in the area at lowest risk wh
variation the MOR is 1 with a larger value indicating greater geographical variationsArea-level interactions
Interactions between geographic remoteness and area disad-
vantage were also not statistically significant for all-cause
(Wald χ2 = 12.22, df = 11, p = 0.347) and CRC-specific (Wald
χ2 = 8.83, df = 11, p = 0.638) survival, implying that the im-
pact of socioeconomic disadvantage on both all-cause and
CRC-survival were similar for urban and rural CRC patients.
Area-level variance
The null models indicated significant evidence of geo-
graphical variation in both all-cause (Model 1; p < 0.001)
and CRC-specific (Model 7; p = 0.001) survival across 478
SLAs in Queensland (Table 2). However, when successively
adding the individual-level and area-level variables to the
models, the amount of unexplained geographical variation
decreased, to which point it became non-significant for the
final model for both all-cause (Model 5, p = 0.118) andvariations in all-cause and colorectal cancer-specific
(95% CrI)3 p value % reduction variance4 MOR (95% CrI)5
39) <0.001 - 1.16 (1.13, 1.21)
18) 0.042 56 1.10 (1.08, 1.14)
14) 0.101 72 1.08 (1.05, 1.12)
14) 0.078 76 1.08 (1.03, 1.12)
12) 0.118 80 1.07 (1.03, 1.11)
12) 0.128 80 1.07 (1.03, 1.11)
34) 0.001 - 1.15 (1.10, 1.19)
12) 0.044 61 1.09 (1.05, 1.11)
07) 0.231 86 1.05 (1.02, 1.08)
11) 0.173 81 1.06 (1.02, 1.10)
08) 0.231 91 1.04 (1.02, 1.09)
11) 0.298 86 1.05 (1.02, 1.10)
tilevel models.
gnosis, sex, occupation, marital and Indigenous status, cancer stage, site,
ess; Models 4 and 10 also adjusted for area disadvantage; Models 5 and 11
area-level interactions and all explanatory factors in Models 5 or
) is better supported by the data while those with difference of 3–5 units can
lative to the null model.
MOR is the median value of the distribution of the odds ratio between an
en randomly selecting two individuals from two different areas. In absence of
.
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statistical significance was reflected in the relatively low
values (i.e. close to one) of the MORs in Table 2.
Impact of area-level covariates on area-level variation
All of the IOR-80 intervals (Table 3) by area-disadvantage
were relatively ‘narrow’ and did not contain 1, suggesting
that the impact that area-level disadvantage quintiles had
on survival was large relative to the clustering effect of the
SLAs. The impact of remoteness was less clear; while
there was no evidence (IOR interval contained 1) that the
difference between major cities and inner regions had an
impact on the area-level variation; there was some differ-
ence between major city and remote areas.
Fixed parameter estimate
Independent of individual-level factors, both area disad-
vantage (p = 0.004) and geographic remoteness (p < 0.001)
were significantly associated with CRC-cancer specific sur-
vival (Table 4). Statistically significant associations were
also evident between area disadvantage (p < 0.001) and
remoteness (p =0.003) with all-cause survival.
Compared to CRC patients from the least disadvantaged
quintile (Quintile 5), residents of the remaining fourTable 3 Interval odds ratios (80%) for the influence of
area disadvantage or remoteness on geographical







Model 53 Model 113
Area-Remoteness Index
of Australia (ARIA)
Major city 1.00 1.00
Inner regional 0.89, 1.15 0.90, 1.06
Outer regional 0.96, 1.24 1.06, 1.25
Remote4 1.01, 1.31 1.14, 1.34
Index of Relative socioeconomic
advantage and disadvantage (IRSAD)
Quintile 5 (least disadvantaged) 1.00 1.00
Quintile 4 1.01, 1.30 1.03, 1.21
Quintile 3 1.04, 1.34 1.06, 1.25
Quintile 2 1.07, 1.39 1.11, 1.30
Quintile 1 (most disadvantaged) 1.10, 1.42 1.13, 1.39
1 IOR-80 is the 80% interval odds ratio which quantifies the contribution of
area-level explanatory factors to the variations in survival between areas. If the
interval does not include 1.0 it indicates that the effect of the area-level
variable is large relative to the clustering effect of the SLAs.
2 IOR-80 is calculated with respect to the reference category for each area-
level explanatory variable.
3 Estimates derived from best fitting fully adjusted Models 5 and 11
respectively (see text for details).
4 Includes remote and very remote categories.quintiles had worse CRC-specific (OR 1.12, 1.15, 1.20,
1.23 for Quintiles 4, 3, 2 and 1 respectively) and all-cause
survival (OR ranging from 1.14 to 1.25 by quintiles of in-
creasing disadvantage). Compared to those from major cit-
ies, living in outer regional and remote areas was also
associated with significantly poorer all-cause (outer re-
gional: OR 1.09, remote: OR 1.15) and CRC-specific sur-
vival (outer regional: OR 1.15, remote: OR 1.24).
In addition to increasing age and stage, all other
individual-level clinical and socio-demographic factors
(except site were independent predictors of both all-
cause and CRC-specific survival in multivariate analysis.
(Table 4) Finally CRC survival decreased with time (with
a quadratic relationship between survival and years of
follow-up). There was little difference in the parameter
estimates for all the fixed effects across each set of
models (full results not shown).
The sensitivity analyses for stage (full results not shown)
suggested that the independent association of area-level
remoteness and disadvantage with both all-cause and
CRC-specific survival remained regardless of the proposed
assumptions for the true distribution of cancer stage at
diagnosis.
Discussion
In this large population-based study of CRC patients in
Queensland we found that survival outcomes depended
on where patients lived at diagnosis, and that this dispar-
ity remains after adjustment for important individual-
level socio-demographic and clinical factors. Specifically
our results demonstrated that residents of more disad-
vantaged and remote areas had significantly lower all-
cause and CRC-specific survival five years after diagnosis
of CRC, irrespective of their individual characteristics
and irrespective of the clinical characteristics of their
cancers, including cancer stage at diagnosis.
There are a number of potential explanations for the
observed survival disparity including possible differences
in management patterns, although without more informa-
tion these remain speculative. Geographical barriers and
poorer health infrastructure [12] have previously been
associated with lower receipt of multimodal therapies and
lower survival of CRC patients in rural or (outer) regional
Australia compared to major cities, [8,42,43] and, in-
ternationally, the impact on patient outcomes of variations
in hospital volume and clinical experience are well-
documented [44-46] in that higher caseloads and increased
specialization generally improve CRC-related outcomes.
All major centers of oncological care in Queensland are lo-
cated in metropolitan areas and this is likely to be part of
the explanation for the relatively better outcomes in major
city and inner regional areas.
However we also found strong evidence of lower sur-
vival outcomes for people living in socioeconomically
Table 4 Geographic remoteness, area-disadvantage and the adjusted odds of all-cause and colorectal cancer mortality
in Queensland, 1997–2007
All-cause p Colorectal cancer-specific p
sub group OR (95% CrI)1 OR (95% CrI)1
Area-Remoteness Index of Australia (ARIA) =0.004 =0.003
Major city 1.00 1.00
Inner regional 0.95 (0.88, 1.02) 0.98 (0.90, 1.06)
Outer regional 1.09 (1.01, 1.18) 1.15 (1.05, 1.25)
Remote2 1.15 (1.02, 1.28) 1.24 (1.07, 1.42)
p-value
Relative socioeconomic advantage and
disadvantage (IRSAD)
<0.001 <0.001
Quintile 5 (least disadvantaged) 1.00 1.00
Quintile 4 1.14 (1.03, 1.23) 1.12 (1.01, 1.23)
Quintile 3 1.18 (1.08, 1.29) 1.15 (1.03, 1.27)
Quintile 2 1.22 (1.11, 1.34) 1.20 (1.07, 1.33)
Quintile 1 (most disadvantaged) 1.25 (1.10, 1.36) 1.23 (1.09, 1.30)
Time (years after diagnosis) 0.45 (0.41, 0.50) <0.001 0.47 (0.42, 0.52) <0.001
Time-squared ([years after diagnosis]squared]) 1.07 (1.05, 1.08) <0.001 1.04 (1.02, 1.07) <0.001
Age group <0.001 <0.001
20 to 49 0.24 (0.21, 0.27) 0.37 (0.33, 0.43)
50 to 59 0.29 (0.26, 0.32) 0.45 (0.41, 0.51)
60 to 69 0.42 (0.39, 0.46) 0.59 (0.54, 0.65)
70 to79 0.68 (0.63, 0.73) 0.77 (0.70, 0.84)
80 to 85 1.00 1.00
Gender <0.001 <0.001
Male 1.00 1.00
Female 1.08 (1.02, 1.14) 1.17 (1.10, 1.25)
Marital status <0.001 <0.001
Married 1.00 1.00
Never married/ single 1.33 (1.21, 1.46) 1.29 (1.16, 1.43)
Widowed 1.11 (1.03, 1.19) 1.06 (0.97, 1.14)
Divorced 1.18 (1.08, 1.29) 1.17 (1.06, 1.29)
Separated 0.94 (0.77, 1.13) 0.89 (0.71, 1.09)
Not stated 1.32 (1.02, 1.68) 1.41 (1.03, 1.85)
Occupation category <0.001 <0.001
Professional 1.00 1.00
White collar 1.11 (1.02, 1.20) 1.07 (0.97, 1.17)
Blue collar 1.38 (1.29, 1.49) 1.36 (1.25, 1.47)
Not in labor force 0.46 (0.43, 0.50) 0.50 (0.46, 0.54)
Not stated/ Inadequately
described
0.35 (0.32, 0.39) 0.34 (0.31, 0.38)
Country birth3 =0.045 =0.040
Australia 1.00 1.00
Other english-speaking 0.96 (0.90, 1.02) 0.99 (0.92, 1.06)
Non-english-speaking 0.88 (0.76, 0.97) 0.87 (0.74, 0.86)
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Table 4 Geographic remoteness, area-disadvantage and the adjusted odds of all-cause and colorectal cancer mortality
in Queensland, 1997–2007 (Continued)
Indigenous status <0.001 <0.001
Non indigenous 1.00 1.00
Indigenous 1.16 (0.89, 1.49) 1.09 (0.99, 1.44)
Not stated 0.45 (0.39, 0.51) 0.43 (0.36, 0.50)
Site4 =0.076 =0.134
Proximal (R) colon 1.02 (1.01, 1.08) 1.01 (0.99, 1.13)
Distal (L) colon 1.03 (0.96, 1.10) 0.97 (0.93, 1.00)
Colon NOS 1.04 (1.01, 1.16) 1.02 (0.99, 1.07)
Rectal 1.00 1.00
Stage <0.001 <0.001
Stage A 1.00 1.00
Stage B 1.61 (1.47, 1.77) 2.44 (2.15, 2.77)
Stage C 3.17 (2.91, 3.45) 6.09 (5.40, 6.85)
Stage D 11.41 (10.30, 12.57) 23.25 (20.39, 26.43)
Unknown stage 2.09 (1.86, 2.34) 3.59 (3.09, 4.14)
Differentiation <0.001 <0.001
Well differentiated 1.00 1.00
Moderate differentiated 1.14 (1.01, 1.29) 1.37 (1.18, 1.60)
Poor differentiated 1.64 (1.44, 1.87) 2.07 (1.77, 2.43)
Not stated differentiation 1.25 (1.09, 1.43) 1.46 (1.24, 1.73)
Surgical margins <0.001 <0.001
Clear 1.00 1.00
Positive 1.42 (1.19, 1.66) 1.55 (1.27, 1.85)
Unknown margin 1.84 (1.68, 2.01) 1.97 (1.79, 2.17)
CrI: credible interval for posterior distributions from Markov Chain Monte Carlo multilevel models.
1 Estimates derived from best fitting fully adjusted Models 5 and 11 (see text for details).
2 Includes remote and very remote categories.
3 Other English-speaking: those born in New Zealand, United Kingdom, Ireland, or North America; non-English-speaking: those not born in Australia, New Zealand,
United Kingdom, Ireland or North America.
4 Colorectal sites defined as: proximal colon (ICDO3: C180 to C184), distal colon (ICDO3: C185-C187), unspecified colon (ICDO3: C188-C189) and rectal (ICDO3:
C19-C20, C218).
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other individual and clinical characteristics, meaning
that distance is not the only explanation. While Australia
does have universal free hospital cover, previous research
has shown that colorectal cancer patients who seek med-
ical care in private hospitals have experienced better out-
comes [10]. It is also possible that these area-level
effects may at least partially reflect geographical differ-
ences in the distribution of other important patient char-
acteristics that are known to influence prognosis, such
as overweight, physical inactivity, smoking, dietary pat-
terns, comorbidities and general health status as well
as treatment [4-6,9,42]. For example people living in so-
cioeconomically disadvantaged or rural areas are more likely
to engage in high risk behaviors such as smoking and de-
creased physical activity [47]. In addition, people living inrural and remote areas of Australia have a higher prevalence
of comorbidities such as diabetes and cardiovascular condi-
tions that can significantly impact the clinical management
and prognosis for CRC patients [48]. The impact of selected
individual risk factors on geographical differences in all-
cause mortality for Australia has been recently quantified
and suggests that interventions targeted at modifiable health
factors could translate to a substantial reduction (around
36-45%) in the regional mortality differentials [49].
Since the vast majority of people diagnosed in Queensland
over the current study period (1996–2007) were symptom-
atic [50] and the gradual implementation of the National
Bowel Cancer Screening Program [51] only began in late
2006; any influence that screening had on current results
would be limited. However geographical differences in par-
ticipation rates may impact CRC outcomes in the future.
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http://www.biomedcentral.com/1471-2407/13/493Important strengths of this study include the
population-based coverage and high quality of inci-
dence data from the Queensland cancer registry [17]
and inclusion of all routinely available covariates in
the analysis. Disease stage was clinically coded from
pathological forms. All-cause survival was estimated, along
with CRC-specific survival, thereby avoiding the intrinsic
dependence of cause-specific survival on cause-of death
coding [52]. The multilevel design takes into account the
hierarchical data structure and allows the simultaneous
estimation of both individual- and area-level effects on
survival, something that is not possible in ecological
studies. The estimated random effects from MCMC si-
mulations were quantified using MOR [30,53] to assess
the magnitude of geographic variation in a meaningful
way. In addition the IOR-80 interval which integrates
area-level fixed and random terms was used to quantify
area-level covariate effects in comparison to the unex-
plained variation [30].
However the Queensland cancer registry does not col-
lect information on potential confounders including but
not limited to treatment, life style, comorbidities, family
history, ongoing surveillance, stress, inflammation and
other measures of individual socioeconomic status (in-
come and education) [4,5,54-56]. Different measures of
socioeconomic status are not interchangeable and can
have a diverse impact on health outcomes [57]. The
occupation measure used for the current study was lim-
ited in its sensitivity and precision since it was not
possible to disaggregate the ‘Not stated/Inadequately
described category into more homogenous groupings
such as ‘home duties’, ‘retired’ or unemployed’ based on
available information. Around 16% of cases could not be
staged and are likely to be fairly advanced at diagnosis
(based on 5-year survival estimates by stage) however
sensitivity analyses confirmed that the results were con-
sistent under the various assumptions of the missing
stage information.
Conclusions
This study has demonstrated that people diagnosed with
CRC in rural and disadvantaged areas have significantly
poorer survival than those living in urban and affluent
areas, independently of cancer stage and other individual-
level characteristics. Addressing this survival disadvantage
will require as a first step a commitment of resources to
clarify and quantify the main causes for this disparity, and
it is hoped that these results provide the necessary motiv-
ation and impetus for this to happen. The causes of these
inequalities are likely to be complex and difficult to
unravel, however, a better understanding is essential to in-
form the development of interventions to improve survival
in rural and disadvantaged areas to the level of the rest of
the population.Additional files
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